Halberd CEO Mid-Quarter Update

Rhea-AI Summary

Halberd Corporation provides a mid-quarter update on its ongoing projects, including progress on preclinical model testing for its nasal spray for Traumatic Brain Injury (TBI) and eradication of antibiotic-resistant strains of Candida auris and E. coli using laser technology. The company has also submitted multiple funding proposals and applications for support.

Positive

• Halberd Corporation is progressing rapidly on several projects, including the development of a patent-pending nasal spray for TBI. The company has completed Phase I of preclinical model testing and will move on to Phase II to test the effectiveness of the spray. This could positively impact the stock price if successful.
• The eradication of antibiotic-resistant strains of Candida auris and E. coli using Halberd's laser technology demonstrates the potential of the company's patented and patent-pending extracorporeal laser eradication methodology. This could positively impact the stock price as it showcases the effectiveness of Halberd's technology.

Negative

• None.

JACKSON CENTER, PA / ACCESSWIRE / May 31, 2023 / Halberd Corporation (OTC PINK:HALB) has been progressing rapidly on several projects in so many areas that this mid-quarter update is intended to bring the public up to date on a few of the most significant efforts.

Mississippi State University (MSU) has completed the impacts and sample collection for Phase I of the ongoing preclinical model testing. Based on the analysis of the samples, a baseline impact level will be selected that will be used in Phase II of the testing. Phase II will test the effectiveness of Halberd's patent-pending nasal spray. The spray is designed to be administered within hours of a Traumatic Brain Injury (TBI) by directly targeting the associated antigens in the brain and cerebrospinal fluid (CSF) and mitigate their negative effects.

Youngstown State University (YSU) demonstrated eradication of additional strains of antibiotic resistant Candida auris provided by the Centers for Disease Control and Prevention (CDC) through application of Halberd's patented and patent-pending extracorporeal laser eradication methodology. These results mimic the results of tests on earlier tested strains.

This past week, YSU researchers replicated the earlier eradication test results on E. coli by using as little as 10% of the laser power used in the initial eradication testing. The ability to achieve the same level of antigen eradication at a fraction of the power means even less collateral damage to surrounding constituents in blood or CSF.

As mentioned in Halberd's First Quarter 2023 CEO Update Letter, Halberd had submitted four abstracts to the proposal submission system for the National Institute of Health (NIH) Advance Research Projects Agency - Health (ARPA-H) Open Office Broad Agency Announcement Solicitation. Each proposal for funding covers a different aspect of Halberd's technology under development. In the last month, Halberd has prepared and submitted an additional three abstracts for consideration, bringing the total to seven, while considering creation of an eighth proposal.

Halberd has also submitted applications for funding support from a disease-specific association and will provide updates via press releases and emails to Halberd's subscribers.

Halberd continues to make progress on advancing its patented and patent pending technologies with a focus on developing effective treatments for some of today's most debilitating disease and neurodegenerative conditions.

To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.

About Youngstown State University
Youngstown State University is a public university in Youngstown, Ohio, and is composed of 5 undergraduate colleges. The University has over 150 undergraduate degree programs and 50 graduate degree programs serving over 12,000 students in studies up to the doctoral level. Beyond its current student body, the university has more than 125,000 alumni across the country and around the world.

About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
(C) 2023, Halberd Corporation

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/758212/Halberd-CEO-Mid-Quarter-Update

FAQ

What projects is Halberd Corporation working on?

Halberd Corporation is working on several projects, including the development of a nasal spray for Traumatic Brain Injury (TBI) and the eradication of antibiotic-resistant strains of Candida auris and E. coli using laser technology.

What is the progress on the nasal spray for TBI?

Halberd Corporation has completed Phase I of preclinical model testing for the nasal spray and will move on to Phase II to test its effectiveness.

How is Halberd Corporation eradicating antibiotic-resistant strains?

Halberd Corporation is using its patented and patent-pending extracorporeal laser eradication methodology to eradicate antibiotic-resistant strains of Candida auris and E. coli.

Has Halberd Corporation submitted any funding proposals?

Yes, Halberd Corporation has submitted four abstracts to the National Institute of Health (NIH) Advance Research Projects Agency - Health (ARPA-H) and is considering submitting more proposals.

Is Halberd Corporation making progress on its technologies?

Yes, Halberd Corporation continues to make progress on advancing its patented and patent-pending technologies for the treatment of various diseases and neurodegenerative conditions.